Types of COVID-19 Vaccinations

Hundreds of Covid-19 vaccinations are in development, and many have shown significant efficacy in phase III clinical studies. Each of them is attempting to accomplish the same goal - viral immunity, and some might be able to halt transmission. They do this by inducing an immune reaction to an antigen on the virus. In the instance of COVID-19, the antigens are usually the virus's distinctive spike protein, which generally utilizes to aid in its invasion of human cells. A COVID19 vaccine is a vaccine designed to give acquired immunity against coronavirus illness coronavirus 2 (SARSCoV2), which causes coronavirus disease 2019 (COVID19). The table below summarizes many COVID-19 vaccines.

Serial No	Name of Vaccine
1.	SinoVac and SinoPharm
2.	Sputnik V from Gamaleya
3.	Pfizer & BioNTech
4.	AstraZeneca-Oxford
5.	Moderna
6.	Johnson & Johnson

Each kind of COVID-19 vaccination works differently in terms of introducing antigens into your body. Antigens are distinct characteristics of SARS-CoV-2 infection. The antigen elicits a particular immune response, which develops immunological memory, preparing your body to fight SARS-CoV-2 in the future.

SinoVac and SinoPharm

Sinovac, a Beijing-based biopharmaceutical firm, is the manufacturer of the CoronaVac inactivated vaccine. CoronaVac is a vaccination that has been inactivated. It utilizes a dead form of the SARS-CoV-2 virus to prevent replication. Still, it leaves the surface spiking protein intact to stimulate the body's immune system to produce antibodies to defend against an invading live virus. It works by exposing the human immune response to the virus through dead viral particles without triggering a severe illness reaction (Baraniuk, 2021).

This vaccination has several disadvantages. During 28 days of the next dosage, the most frequently reported adverse event was injection site discomfort, which occurred in 13–21% of cases, depending on the dosage schedule. Other COVID-19 vaccinations, including Sinopharm's two inactivated COVID-19 vaccines, are associated with injection site responses. Additionally, tiredness, diarrhea, and muscular discomfort may occur. The majorities of these adverse effects were minor and lasted no more than two days. Additionally, individuals who get CoronaVac report fewer fever cases than those who get alternative COVID-19 vaccines, including Moderna's mRNA-based vaccine and Oxford-and AstraZeneca's CanSino's viral vector vaccines (Baraniuk, 2021).

The benefit of this vaccination is that, according to interim data, it is 79.34 percent effective in preventing individuals from getting the illness. It has received approval in some nations, including China, Pakistan, and the United Arab Emirates. Sinovac's vaccine demonstrated effectiveness levels ranging from 50.65 percent to 83.5 percent in studies conducted in Brazil, Turkey, and Indonesia. The two China-made vaccinations have been in high demand in some emerging nations where access to injections manufactured by Western rivals is restricted.

Sputnik V from Gamaleya

This refers to a viral two-vector vaccination built on these dual human adenoviruses — a common cold virus – that include the gene encoding the SARS-CoV-2 full-length spiking protein (S) to elicit an immune response. A cellular microbiologist team created the Gam-COVID-Vac vaccine at the Gamaleya Research Institute of Epidemiology and Microbiology, which the government funds. The 'V' within the designation stands for 'Victory against COVID-19. The injection can be prepared in two aspects: as a ready usable water solution that has been freezing at the normal household refrigerator storage conditions of 18°C, 0°F or maybe less; or as a refrigerator-dried flour called "Gam-COVID-Vac-Lyo" that has been frozen at a temperature more than freezing, 2–8°C or maybe 36–46°F, at the normal home freezer temperature. Before used, the frozen-dried powders must be reconstructed using water (Baraniuk, 2021).

Adenoviruses are a kind of virus linked with the flu virus and other diseases, one of their advantages. They act as carriers for the DNA information necessary to generate the SARS-CoV-2 virus's spike protein in the body. This subsequently stimulates the creation of antibodies against the spiking protein, priming the immune system for an upcoming infection. Each of the two doses has a distinct strain of adenovirus: the first dosage contains type-26 (Ad26), followed by a booster dosage that contains type-5 (Ad5) (Ad5). The aim of employing two distinct kinds is to reduce the likelihood that the body would build antibodies towards the adenovirus following the first dosage, rendering the second dosage useless. Concerning its disadvantages, the most often reported adverse responses are flu-like sickness, headache, tiredness, and injection site responses (Baraniuk, 2021).

Pfizer & BioNTech

It is a COVID-19 vaccination based on mRNA that is marketed under the trade name Comirnaty. It is approved for use in individuals aged 12 years or older in certain countries and those aged 16 years or older in others to defend against infection with the SARS-CoV-2 virus that brings COVID-19. The vaccine was created by BioNTech, a German firm, collaborating with Pfizer, an American firm, which assisted with clinical testing, logistics, and production. Discomfort at the injection site, fatigue, headache, muscular discomfort, chills, muscle aches, and fever were the most frequently reported adverse effects, which usually lasted several days. Notably, more individuals had these adverse effects following the second dosage than after the first dose, indicating that vaccination providers and receivers should anticipate some negative effects after either dosage, especially after the second dose. In terms of efficacy, research demonstrates that its injection was 94% successful in avoiding critical care unit hospitalizations and fatalities and 78% effective at reducing infection rates (De Soto, 2020).

AstraZeneca-Oxford

The Oxford–AstraZeneca COVID-19 vaccination, codenamed AZD1222, refers to a viral vector vaccine to prevent COVID-19. It is marketed under the trade terms Covishield and Vaxzevria, among others. It is ingested intramuscularly and was manufactured by Oxford University alongside AstraZeneca. It utilizes the modified chimp adenovirus ChAdOx1 as a vector. The vaccine is 76.0 percent effective in preventing symptomatic COVID-19 infection starting 22 days after the first dose and 81.3 percent effective after the second dose. Another study showed that the vaccination is 66% efficacious against the Alpha version (lineage B.1.1.7) and 60% effective against the Delta version for symptomatic COVID-19 transmission after the second dose (lineage B.1.617.2).

The vaccination has a favorable safety record, with common adverse events including injection site discomfort, headache, and nausea that often resolve within a few days. Anaphylaxis occurs more infrequently. In very rare instances, about 1 in 100,000 individuals, the vaccination has been linked to an elevated danger of blood clots when combined with low platelet counts (Dyer, 2021).

Moderna

Moderna's COVID-19 vaccine, named mRNA-1273, is a US-developed COVID-19 vaccine. It is used to prevent individuals 18 years and older from contagion with the SARS-CoV-2 infection that causes COVID-19. The vaccine is intended to be delivered in two 0.5 mL doses a month apart by intramuscular vaccination. It is an RNA injection comprising nucleoside-modified messenger RNA (modRNA) encoding the SARS-CoV-2 spiking protein enclosed in fat nanoparticles (Mahase, 2020).

Efficacy of the vaccination becomes evident about two weeks following the initial dosage. Full vaccination, two weeks just after the second dose, results in a 94.1 percent efficacy rate. Furthermore, the vaccination group has zero instances of severe COVID19. This effectiveness has been characterized as "astonishing" and "bordering on historic" with a respiratory virus vaccination and is comparable to the Pfizer–BioNTech COVID-19 immunizations effectiveness Estimates of efficacy were close across age ranges, genders, ethnic and racial groupings, and individuals with medical comorbidities linked with an increased incidence of severe COVID19. The study included only people aged 18 or older. Efficacy and safety studies are ongoing in children ages 0–11 (KidCOVE) but rather 12–17 (KidCOVE) (TeenCOVE).

Pain at the site of injection, fatigue, headache, malaise, arthralgia, chills, vomiting, axillary oedema, fever, bloating at the site of injection, and erythema at the site of injection were all reported as adverse reactions following the administration of Moderna COVID-19 Immunization in a clinical trial. Severe allergic responses, including anaphylaxis, are being recorded after the infusion of Moderna COVID-19 Vaccine outside of clinical studies during mass immunization. Additional side effects, some of which may be severe, may become evident when the Moderna COVID-19 Vaccination is used more widely (Mahase, 2020).

Johnson & Johnson

It refers to a viral vector vaccination built on a mortal adenovirus modified to include the gene encoding the SARS-CoV-2 infection's spiking protein that produces COVID-19. The

immunity system creates antibodies in reaction to this spiking protein. This vaccination is administered in a single dosage and does not require freezing. The J&J vaccine's efficacy was evaluated in a clinical study comprising more than 40,000 individuals. The J&J vaccination was shown to prevent mild to severe to critical instances of COVID-19 in this clinical study (Sharun et al., 2021).

The vaccine's most frequent adverse effects in clinical studies were often mild or moderate, began within two days following immunization, and resolved within one or two days. These include injection site discomfort, headache, fatigue, muscular discomfort, and nausea, which affect over 1 in 10 individuals. Coughing, joint discomfort, fever, chills, erythema, and edema at the site of injection happened in fewer than one-tenth of a percent of individuals. Sneezing, tremors, throat discomfort, rash, sweating, muscular weakness, arm and leg discomfort, backache, weakness, and overall malaise occurred in fewer than one in every 100 individuals. Hypersensitivity and itchy rash are uncommon adverse effects.

There is a para-anxiety regarding the future vaccine variants' ineffectiveness in the UK, India, and Brazil. This is that viruses evolve constantly, and the majority of changes are insignificant. Some are even toxic to the virus. However, certain changes may increase the disease's infectiousness or danger - and these variants tend to predominate.

References

Baraniuk, C. (2021). What do we know about China's COVID-19 vaccines? *BMJ*, n912. https://doi.org/10.1136/bmj.n912

Baraniuk, C. (2021). COVID-19: What do we know about sputnik V and other Russian vaccines? *BMJ*, n743. https://doi.org/10.1136/bmj.n743

De Soto, J. A. (2020). Evaluation of the Moderna, Pfizer/BioNtech, Astrazeneca/Oxford and sputnik V vaccines for COVID-19. https://doi.org/10.31219/osf.io/e4rqu

Dyer, O. (2021). COVID-19: Moderna and Pfizer vaccines prevent infections as well as symptoms, CDC study finds. *BMJ*, n888. https://doi.org/10.1136/bmj.n888

Mahase, E. (2020). COVID-19: Pfizer and BioNTech submit vaccine for US authorisation. *BMJ*, m4552. https://doi.org/10.1136/bmj.m4552

Sharun, K., Singh, R., & Dhama, K. (2021). Oxford-astrazeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries. *Annals of Medicine and Surgery, 65*, 102264. https://doi.org/10.1016/j.amsu.2021.102264